FDA label
What is Ojjaara used for?
Ojjaara contains momelotinib. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Ojjaara?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Ojjaara, tablet
Indications and Usage, quoted from the label by GlaxoSmithKline LLC (NDA216873). Cross-references to other label sections are left out.
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Source: DailyMed label, set id 4a672fd1-eb7b-4aa9-9b23-845e4b5dc400, version 9, effective July 20, 2026. NDC 81864-101, one of 3 listings for this product.
Questions
What is Ojjaara used for?
The FDA label says: “OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.”
What drug class is Ojjaara?
FDA lists momelotinib in the Kinase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.